Rifaximin: An Antibiotic with Important Biologic Effects

被引:14
作者
DuPont, H. L. [1 ,2 ,3 ,4 ]
机构
[1] Univ Texas Hlth, Sch Publ Hlth, Ctr Infect Dis, Houston, TX USA
[2] Univ Texas Hlth, Sch Med, Houston, TX USA
[3] Kelsey Res Fdn, Houston, TX USA
[4] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
关键词
Bile salts; Crohn's disease; hepatic encephalopathy; inflammatory bowel disease; Rifaximin; PREGNANE-X-RECEPTOR; INTESTINAL BACTERIAL OVERGROWTH; INFLAMMATORY-BOWEL-DISEASE; IN-VITRO ACTIVITY; CLOSTRIDIUM-DIFFICILE INFECTION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ESCHERICHIA-COLI; HEPATIC-ENCEPHALOPATHY; CROHNS-DISEASE;
D O I
10.2174/1389557515666150722110201
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Rifaximin is a poorly absorbed rifamycin drug with unique pharmacokinetic properties: bile solubility making it highly active against pathogenic and non-pathogenic bacterial flora in the bile-rich small bowel and low water solubility making it active only against highly susceptible bacteria, primarily anaerobes, in the aqueous colon. The drug has anti-inflammatory gut mucosal stabilization properties that are important to its sustained effects in non-infectious diseases. Rifaximin is used chronically or recurrently for hepatic encephalopathy and diarrhea-predominant irritable bowel syndrome. Monitoring of long-term use of rifaximin for development of resistance and then determining whether developed resistance is associated with reduced efficacy are needed. Studies of changes of intestinal flora during therapy and the health implications of these changes are also needed.
引用
收藏
页码:200 / 205
页数:6
相关论文
共 59 条
[1]   Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation [J].
Bajaj, Jasmohan S. ;
Hylemon, Phillip B. ;
Ridlon, Jason M. ;
Heuman, Douglas M. ;
Daita, Kalyani ;
White, Melanie B. ;
Monteith, Pamela ;
Noble, Nicole A. ;
Sikaroodi, Masoumeh ;
Gillevet, Patrick M. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2012, 303 (06) :G675-G685
[2]  
Bauer TM, 2002, AM J GASTROENTEROL, V97, P2364
[3]   The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients [J].
Bibiloni, Rodrigo ;
Mangold, Marco ;
Madsen, Karen L. ;
Fedorak, Richard N. ;
Tannock, Gerald W. .
JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (08) :1141-1149
[4]   Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis [J].
Brigidi, P ;
Swennen, E ;
Rizzello, F ;
Bozzolasco, M ;
Matteuzzi, D .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (03) :290-295
[5]   Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles [J].
Brown, Eric L. ;
Xue, Qiong ;
Jiang, Zhi-Dong ;
Xu, Yi ;
DuPont, Herbert L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :388-396
[6]  
Cheng J., 2010, J PHARM EXP THER
[7]   Interaction between rifaximin and dietary fibre in patients with diverticular disease [J].
D'Inca, R. ;
Pomerri, F. ;
Vettorato, M. G. ;
Dal Pont, E. ;
Di Leo, V. ;
Ferronato, A. ;
Medici, V. ;
Sturniolo, G. C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (07) :771-779
[8]   Bile Acids Improve the Antimicrobial Effect of Rifaximin [J].
Darkoh, Charles ;
Lichtenberger, Lenard M. ;
Ajami, Nadim ;
Dial, Elizabeth J. ;
Jiang, Zhi-Dong ;
DuPont, Herbert L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) :3618-3624
[9]   Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations [J].
Debbia, E. A. ;
Maioli, E. ;
Roveta, S. ;
Marchese, A. .
JOURNAL OF CHEMOTHERAPY, 2008, 20 (02) :186-194
[10]  
Dogan B., 2012, INFLAMM BOWEL DIS, P16